• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    AstraZeneca PLC – ADR to Join the NASDAQ-100 Index Beginning February 22, 2022

    2/10/22 5:00:00 PM ET
    $AZN
    $NDAQ
    $XLNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance
    Get the next $AZN alert in real time by email

    NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that AstraZeneca PLC – ADR (NASDAQ:AZN), will become a component of the NASDAQ-100 Index® (NASDAQ:NDX) and the NASDAQ-100 Equal Weighted Index (NASDAQ:NDXE) prior to market open on Tuesday, February 22, 2022. AstraZeneca PLC – ADR will replace Xilinx, Inc. (NASDAQ:XLNX) in the NASDAQ-100 Index® and the NASDAQ-100 Equal Weighted Index.

    For more information about the company, go to https://www.astrazeneca.com.

    About Nasdaq

    Nasdaq (NASDAQ:NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.

    Media Contact

    Emily Pan

    emily.pan@Nasdaq.com

    +1 (646) 637-3964

    Issuer & Investor Contact

    Index Client Services

    Indexservices@Nasdaq.com

    The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq's proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

    - NDAQG -



    Primary Logo

    Get the next $AZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZN
    $NDAQ
    $XLNX

    CompanyDatePrice TargetRatingAnalyst
    Nasdaq Inc.
    $NDAQ
    4/8/2026$92.00Mkt Perform
    Keefe Bruyette
    Nasdaq Inc.
    $NDAQ
    2/26/2026$106.00Hold → Buy
    TD Cowen
    AstraZeneca PLC
    $AZN
    1/27/2026Buy
    Citigroup
    Nasdaq Inc.
    $NDAQ
    11/20/2025$110.00Equal-Weight → Overweight
    Morgan Stanley
    AstraZeneca PLC
    $AZN
    10/27/2025Buy
    Jefferies
    AstraZeneca PLC
    $AZN
    10/16/2025Hold → Sell
    Deutsche Bank
    Nasdaq Inc.
    $NDAQ
    7/25/2025$115.00Neutral → Buy
    UBS
    Nasdaq Inc.
    $NDAQ
    4/17/2025$91.00Neutral → Buy
    Redburn Atlantic
    More analyst ratings

    $AZN
    $NDAQ
    $XLNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Keefe Bruyette resumed coverage on NASDAQ with a new price target

    Keefe Bruyette resumed coverage of NASDAQ with a rating of Mkt Perform and set a new price target of $92.00

    4/8/26 8:37:55 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    NASDAQ upgraded by TD Cowen with a new price target

    TD Cowen upgraded NASDAQ from Hold to Buy and set a new price target of $106.00

    2/26/26 7:10:22 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Citigroup initiated coverage on AstraZeneca

    Citigroup initiated coverage of AstraZeneca with a rating of Buy

    1/27/26 8:43:14 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $NDAQ
    $XLNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History

    NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, June 5, 2026 /CNW/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Ashley Mastronardi delivers the pre-market update on June 5thInvestors are reacting to the May jobs report after the DOW climbed to a record close on Thursday.AstraZeneca (NYSE:AZN) is celebrating its February transfer to the NYSE, the largest transfer by market capitalization in the NYSE's 234-year history.NYSE Live will provide exclusive coverage of CEO Pascal Soriot's remarks

    6/5/26 8:55:00 AM ET
    $AZN
    $ICE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance

    Nasdaq Reports May 2026 Volumes

    NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today reported monthly volumes for May 2026 on its Investor Relations website. A data sheet showing this information can be found at: https://ir.nasdaq.com/financials/volume-statistics.  About NasdaqNasdaq (NASDAQ:NDAQ) is a leading technology platform that powers the world's economies. We architect the infrastructure of the world's most modern markets, power the innovation economy, and build trust in the financial system. We empower economic opportunity by designing and deploying advanced technology, data, and intelligence solutions that enable our clients to capture opportunities, navigate risk, and strengthen resilience.

    6/3/26 4:05:00 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Nasdaq Resumes Trading in TJGC Group Limited

    NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (NASDAQ:NDAQ) announced that trading will resume in TJGC Group Limited (NASDAQ:TJGC) at 12:00 p.m. Eastern Time on June 3, 2026. Trading in the company's ordinary shares was halted on May 15, 2026 at 18:50:47 Eastern Time. For news and additional information about the company, please contact the company directly or check under the company's symbol using InfoQuotesSM on the Nasdaq® Web site. For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com. Nasdaq Contact: Nasdaq MarketWatchdl-NasdaqMarketWatch@nasdaq.com NDAQO

    6/3/26 11:30:00 AM ET
    $NDAQ
    $TJGC
    Investment Bankers/Brokers/Service
    Finance
    Advertising
    Consumer Discretionary

    $AZN
    $NDAQ
    $XLNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Torgeby Johan bought $958,320 worth of shares (12,000 units at $79.86), increasing direct ownership by 42% to 40,797 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    2/19/26 4:00:18 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Large owner Investor Ab bought $15,835,040 worth of shares (200,000 units at $79.18) (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    2/13/26 3:56:39 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Director Zollar Alfred W bought $203,970 worth of shares (2,542 units at $80.24), increasing direct ownership by 5% to 49,293 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    11/14/24 4:29:16 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    SEC Filings

    View All

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    6/1/26 10:10:07 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    6/1/26 10:06:30 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    5/29/26 6:43:39 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $NDAQ
    $XLNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Sharma Mani sold $2,209,482 worth of Ordinary Shares (11,893 units at $185.78), decreasing direct ownership by 38% to 19,262 units (SEC Form 4)

    4 - ASTRAZENECA PLC (0000901832) (Issuer)

    5/22/26 4:05:16 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pres. Capital Access Platforms Griggs Pc Nelson sold $471,714 worth of shares (5,093 units at $92.62), decreasing direct ownership by 2% to 233,798 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    5/20/26 4:05:17 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 31,155 units (SEC Form 4)

    4 - ASTRAZENECA PLC (0000901832) (Issuer)

    5/8/26 4:05:20 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $NDAQ
    $XLNX
    Financials

    Live finance-specific insights

    View All

    BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

    Approval based on BaxHTN Phase III results showing statistically significant and clinically meaningful reduction in systolic blood pressure in patients with uncontrolled or resistant hypertension BAXFENDY 2mg lowered systolic blood pressure by 15.7 mmHg (9.8 mmHg placebo-adjusted) from baseline in BaxHTN trial AstraZeneca's BAXFENDY™ (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to lower blood pressure in adults who are not adequately controlled. This press release features multimedia. View the full release here: https://www.businesswire.com/news

    5/18/26 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AstraZeneca results: Q1 2026

    Strong revenue growth and positive readouts from high-value NMEs reinforce confidence in 2030 ambition AstraZeneca: Revenue and EPS summary   Q1 2026 % Change   $m Actual CER1 - Product Sales 14,386 12 7 - Alliance Revenue 825 29 26 Product Revenue 15,211 13 8 Collaboration Revenue 77 4 - Total Revenue 15,288 13 8 Reported EPS ($) 1.99 6 8 Core2 EPS ($) 2.58 4 5 Key performance elements for Q1 2026 (Growth numbers at constant exchange rates) Total Revenue

    4/29/26 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nasdaq Announces Increase in Quarterly Dividend to $0.31 Per Share

    NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Nasdaq, Inc. (NASDAQ:NDAQ) has declared a regular quarterly dividend of $0.31 per share on the company's outstanding common stock. The dividend is payable on June 26, 2026 to shareholders of record at the close of business on June 12, 2026. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by the Board of Directors. About NasdaqNasdaq (NASDAQ:NDAQ) is a leading technology platform that powers the world's economies. We architect the infrastructure of the world's most modern markets, power the innovation economy, and build trust in the financial

    4/23/26 7:01:00 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

    SC 13G/A - NASDAQ, INC. (0001120193) (Subject)

    11/12/24 3:53:01 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    SEC Form SC 13G filed by Nasdaq Inc.

    SC 13G - NASDAQ, INC. (0001120193) (Subject)

    11/8/24 10:52:39 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

    SC 13G/A - NASDAQ, INC. (0001120193) (Subject)

    11/4/24 1:18:47 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    Leadership Updates

    Live Leadership Updates

    View All

    Lumentum Holdings Inc. to Join the Nasdaq-100 Index® Beginning May 18, 2026

    NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Lumentum Holdings Inc. (NASDAQ:LITE) will become a component of the Nasdaq-100 Index® replacing CoStar Group, Inc. (NASDAQ:CSGP) prior to market open on Monday, May 18, 2026. For additional information, including notifications on changes to any Nasdaq Indexes, please go to https://indexes.nasdaq.com/ About Nasdaq Global Indexes Nasdaq Global Indexes is one of the world's leading index providers, offering a comprehensive suite of rules-based benchmarks and indexes. The Nasdaq-100 Index® — which measures the performance of 100 of the largest Nasdaq-listed non-financial companies — is tracked by more than 2

    5/8/26 8:00:00 PM ET
    $CSGP
    $LITE
    $NDAQ
    Real Estate
    Telecommunications Equipment
    Telecommunications
    Investment Bankers/Brokers/Service

    Sandisk Corporation to Join the Nasdaq-100 Index® Beginning April 20, 2026

    NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Sandisk Corporation (NASDAQ:SNDK) will become a component of the Nasdaq-100 Index® (NDX®) replacing Atlassian Corporation (NASDAQ:TEAM) prior to market open on Monday, April 20, 2026. These updates are consistent with the current Nasdaq-100 Index® methodology, in effect through April 30, 2026. For additional information, including notifications on changes to any Nasdaq Indexes, please go to https://indexes.nasdaq.com/ About Nasdaq Global Indexes Nasdaq Global Indexes is one of the world's leading index providers, offering a comprehensive suite of rules-based benchmarks and indexes. The Nasdaq-100 Inde

    4/10/26 8:00:00 PM ET
    $NDAQ
    $SNDK
    $TEAM
    Investment Bankers/Brokers/Service
    Finance
    Electronic Components
    Technology

    Walmart Inc. to Join the Nasdaq-100 Index® Beginning January 20th, 2026

    NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Walmart Inc. (NASDAQ:WMT), will become a component of the Nasdaq-100 Index® (NDX®), the Nasdaq-100 Equal Weighted™ Index (NDXE™), and the Nasdaq-100 Ex-Tech Sector™ Index (NDXX™) prior to market open on Tuesday, January 20, 2026 - the first trading day following the third Friday of the month. Walmart Inc. will replace AstraZeneca PLC (NASDAQ:AZN) in the Nasdaq-100 Index®, the Nasdaq-100 Equal Weighted Index, and the Nasdaq-100 Ex-Tech Sector Index. AstraZeneca PLC will also be removed from the Nasdaq-100 ESG™ Index (NDXESG™), Nasdaq-100 ex Top 30™​ (NDX70™), Nasdaq-100 ex Top 30​ UCITS™ (NDX70U™), Nasdaq

    1/9/26 8:00:00 PM ET
    $AZN
    $NDAQ
    $WMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance